Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Adv Healthc Mater. 2022 Feb 18;11(8):e2102265. doi: 10.1002/adhm.202102265

Figure 6. dECM microparticles reduce fibrosis and fibroblast activation in post-MI hearts.

Figure 6.

(A) Fibrosis in heart was examined by Masson’s Trichrome staining. (B) Left ventricle wall thickness in the infarct area was higher in dECM microparticles treated group than MI-control. (C) dECM microparticles and dECM hydrogel precursor lowered fibrotic tissue area compared to MI-control. (D) Fibroblast activation was examined by immunostaining for Pdgfr-α and α-SMA. (E) The density of activated fibroblasts was lowered by dECM microparticles treatment compared to MI-control. (F) dECM microparticles and dECM hydrogel precursor reduced fibroblast activation. (Panel B, C, E, F: n=4 per treatment, one-way ANOVA and Tukey’s test. *p<0.05, **p<0.01, ****p<0.0001. All data presented as mean ± SD. Arrows indicate activated fibroblasts; white boxes indicate magnified areas. Single channels of a representative image in panel D are shown in Figure S6B. An example of the location chosen for wall thickness measurement is shown in Figure S7A.)